Ocular Therapeutix Q4 2023 Earnings Report

Ocular Therapeutix EPS Results

• Actual EPS: -$0.28
• Consensus EPS: -$0.28
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Ocular Therapeutix Revenue Results

• Actual Revenue: $14.80 million
• Expected Revenue: $15.31 million
• Beat/Miss: Missed by -$510.00 thousand
• YoY Revenue Growth: N/A

Ocular Therapeutix Announcement Details

• Quarter: Q4 2023
• Date: 3/11/2024
• Time: N/A
• Conference Call Date: Monday, March 11, 2024
• Conference Call Time: 4:00PM ET

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.